ArticlePloS one2026
Fluid sparing effects of chemokine (C-C motif) receptor 1 and 2 antagonists during resuscitation from hemorrhagic shock in rat models.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We described previously that the chemokine (C-C motif) receptor 1 (CCR1) and CCR2 antagonists BX471 and INCB3284 reduce fluid requirements during resuscitation after hemorrhage. Their effects, however, have not been directly compared with each other and consequences of simultaneous blockade of CCR1/2 are unknown. Here we utilized rat (Sprague-Dawley) models of hemorrhagic shock to compare fluid sparing properties when administered individually or in combination and to assess effects on shock tolerance. Series 1: rats were hemorrhaged to a mean arterial blood pressure (MAP) of 30 mmHg for 30 min, followed by blood pressure-directed fluid resuscitation for 6h. At t = 30 min, vehicle (n = 12), BX471 (0.5 µmol/kg, n = 9), INCB3284 (5 µmol/kg, n = 7), or BX471 (0.5 µmol/kg) plus INCB3284 (5 µmol/kg, n = 6) were injected. Series 2: rats were hemorrhaged to a MAP of 30 mmHg for 45 min, injected with vehicle (n = 8), BX471 (0.5 µmol/kg, n = 7) or INCB3284 (5 µmol/kg, n = 5), and observed until t = 225 min. Series 1: cumulative fluid requirements sharply increased between t = 220-300 min and averaged 108±20 mL/kg at t = 390 min with vehicle-treatment. After treatment with BX471, INCB3284 or both, fluid requirements remained constant and averaged 31±8 mL/kg, 51±12 mL/kg and 36.5±8 mL/kg, respectively, at t = 390 min (p < 0.05 vs. vehicle). Mortality was 75% with vehicle treatment and 33%, 57% and 66% with BX471, INCB3284 and BX471 plus INCB3284 treatment, respectively (p > 0.05 vs. vehicle). Measurements of a panel of systemic inflammation markers suggested that BX471 and INCB3284 attenuate release of TNFα and IL6, and enhance release of CCL5 during resuscitation. Series 2: BX471 and INCB3284 treatment did not affect survival times. Our findings confirm fluid sparing effects of BX471 and INCB3284 over 6h of resuscitation, suggest that both drugs exert comparable efficacy to reduce fluid requirements and modulate the systemic inflammatory response to hemorrhage and fluid resuscitation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.